title: The 18-kDa translocator protein (TSPO) disrupts mammary epithelial morphogenesis and promotes breast cancer cell migration.
abstract: Mitochondria play important roles in cancer progression and have emerged as viable targets for cancer therapy. Increasing levels of the outer mitochondrial membrane protein, 18-kDa translocator protein (TSPO), are associated with advancing breast cancer stage. In particular, higher TSPO levels are found in estrogen receptor (ER)-negative breast tumors, compared with ER-positive tumors. In this study, we sought to define the roles of TSPO in the acquisition of breast cancer malignancy. Using a three-dimensional Matrigel culture system, we determined the impact of elevated TSPO levels on mammary epithelial morphogenesis. Our studies demonstrate that stable overexpression of TSPO in mammary epithelial MCF10A acini drives proliferation and provides partial resistance to luminal apoptosis, resulting in enlarged acinar structures with partially filled lumen that resemble early stage breast lesions leading to breast cancer. In breast cancer cell lines, TSPO silencing or TSPO overexpression significantly altered the migratory activity. In addition, we found that combination treatment with the TSPO ligands (PK 11195 or Ro5-4864) and lonidamine, a clinical phase II drug targeting mitochondria, decreased viability of ER-negative breast cancer cell lines. Taken together, these data demonstrate that increases in TSPO levels at different stages of breast cancer progression results in the acquisition of distinct properties associated with malignancy. Furthermore, targeting TSPO, particularly in combination with other mitochondria-targeting agents, may prove useful for the treatment of ER-negative breast cancer.
authors: Cell and Molecular Biology Program, Michigan State University, East Lansing, Michigan, United States of America.
authors: Xiaoting
authors: X
authors: Wu
authors: Kathleen A
authors: KA
authors: Gallo
mesh_terms: D061354:Acinar Cells / Q000187:drug effects / Q000473:pathology; D017209:Apoptosis / Q000187:drug effects; D001570:Benzodiazepinones / Q000494:pharmacology; D001943:Breast Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D048429:Cell Size / Q000187:drug effects; D018450:Disease Progression; D006801:Humans; D007191:Indazoles / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008024:Ligands; D042361:Mammary Glands, Human / Q000378:metabolism / Q000473:pathology*; D009361:Neoplasm Invasiveness; D018079:Receptors, GABA / Q000378:metabolism*
chemical_list: D001570:Benzodiazepinones; D007191:Indazoles; D007546:Isoquinolines; D008024:Ligands; D018079:Receptors, GABA; C499229:TSPO protein, human; C028513:4'-chlorodiazepam; C016371:lonidamine; C037850:PK 11195
references: Cell Calcium. 2007 Jul;42(1):27-39
references: 17174393
references: Nat Rev Clin Oncol. 2010 Dec;7(12):669-70
references: 21116236
references: J Recept Signal Transduct Res. 2003;23(2-3):225-38
references: 14626449
references: Oncogene. 2010 Aug 5;29(31):4399-411
references: 20514022
references: Nat Methods. 2007 Apr;4(4):359-65
references: 17396127
references: Nat Rev Cancer. 2005 Sep;5(9):675-88
references: 16148884
references: Br J Cancer. 1989 Feb;59(2):251-3
references: 2930690
references: J Hepatol. 2004 Nov;41(5):799-807
references: 15519653
references: Biochim Biophys Acta. 2008 Feb;1782(2):118-25
references: 18190798
references: J Mammary Gland Biol Neoplasia. 2006 Oct;11(3-4):205-11
references: 17115263
references: Glia. 2011 Feb;59(2):219-30
references: 21125642
references: Mod Pathol. 2005 Jan;18(1):26-35
references: 15332092
references: Cancer Res. 1999 Feb 15;59(4):831-42
references: 10029072
references: PLoS One. 2011;6(9):e24075
references: 21931642
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Nat Rev Drug Discov. 2010 Jun;9(6):447-64
references: 20467424
references: J Bioenerg Biomembr. 2008 Jun;40(3):199-205
references: 18670869
references: Biochem Pharmacol. 2007 Feb 15;73(4):491-503
references: 17126818
references: Exp Cell Res. 1998 Jun 15;241(2):426-34
references: 9637784
references: Trends Pharmacol Sci. 2006 Aug;27(8):402-9
references: 16822554
references: Haematologica. 2007 Dec;92(12):1631-8
references: 18055986
references: Biochem Pharmacol. 1999 Jul 15;58(2):273-8
references: 10423168
references: Cell. 2002 Oct 4;111(1):29-40
references: 12372298
references: Mol Aspects Med. 2010 Feb;31(1):1-20
references: 19698742
references: Methods. 2003 Jul;30(3):256-68
references: 12798140
references: Oncogene. 2005 Nov 17;24(51):7503-13
references: 16091749
references: Biochemistry. 2009 Jul 28;48(29):6909-20
references: 19552401
references: Korean Diabetes J. 2010 Jun;34(3):146-53
references: 20617074
references: Cancer Res. 1981 Nov;41(11 Pt 1):4661-6
references: 7306982
references: Curr Drug Targets. 2011 Jun;12(6):894-901
references: 21269262
references: Clin Cancer Res. 2004 Mar 15;10(6):2058-64
references: 15041726
references: Biochem Pharmacol. 2000 Aug 1;60(3):397-402
references: 10856435
references: Cancer Res. 2002 Mar 1;62(5):1388-93
references: 11888910
references: Nat Cell Biol. 2001 Sep;3(9):785-92
references: 11533657
references: Oncogene. 2001 Nov 15;20(52):7579-87
references: 11753636
references: Pharmacopsychiatry. 1991 Jan;24(1):8-12
references: 1849286
references: J Biol Chem. 1999 Aug 13;274(33):22932-40
references: 10438458
references: Mol Cell Endocrinol. 2010 Oct 7;327(1-2):1-12
references: 20600583
references: Oncogene. 1999 Apr 22;18(16):2537-46
references: 10353597
references: Cell Commun Signal. 2011 Jul 13;9:17
references: 21752278
references: J Cell Biol. 2003 Oct 27;163(2):315-26
references: 14568991
references: Curr Oncol. 2011 Aug;18(4):e173-9
references: 21874107
references: Endocr Relat Cancer. 2003 Jun;10(2):261-6
references: 12790787